首页> 美国卫生研究院文献>Cancers >Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
【2h】

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies

机译:人源化小鼠是汽车T和汽车NK细胞疗法的临床前评估的珍贵工具

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chimeric antigen receptor (CAR) T-cell therapy represents a revolutionary treatment for hematological malignancies. However, improvements in CAR T-cell therapies are urgently needed since CAR T cell application is associated with toxicities, exhaustion, immune suppression, lack of long-term persistence, and low CAR T-cell tumor infiltration. Major efforts to overcome these hurdles are currently on the way. Incrementally improved xenograft mouse models, supporting the engraftment and development of a human hemato-lymphoid system and tumor tissue, represent an important fundamental and preclinical research tool. We will focus here on several CAR T and CAR NK therapies that have benefited from evaluation in humanized mice. These models are of great value for the cancer therapy field as they provide a more reliable understanding of sometimes complicated therapeutic interventions. Additionally, they are considered the gold standard with regard to assessment of new CAR technologies in vivo for safety, efficacy, immune response, design, combination therapies, exhaustion, persistence, and mechanism of action prior to starting a clinical trial. They help to expedite the critical translation from proof-of-concept to clinical CAR T-cell application. In this review, we discuss innovative developments in the CAR T-cell therapy field that benefited from evaluation in humanized mice, illustrated by multiple examples.
机译:嵌合抗原受体(汽车)T细胞疗法代表血液恶性恶性肿瘤的革命性处理。然而,由于汽车T细胞应用与毒性,耗尽,免疫抑制,长期持久性和低轿车T细胞肿瘤浸润相关,因此迫切需要改善汽车T细胞疗法。克服这些障碍的主要努力目前正在途中。渐进改善的异种移植鼠标模型,支持人血清淋巴系统和肿瘤组织的植入和开发,代表了一个重要的基本和临床前的研究工具。我们将重点关注几辆汽车T和汽车NK疗法,这些疗法受益于人类源化小鼠的评估。这些模型对癌症治疗领域具有很大的价值,因为它们提供了更可靠的有时复杂的治疗干预措施的理解。此外,它们被认为是在进行临床试验之前对安全性,疗效,免疫应答,设计,组合,疲劳,持续性,疲劳,持续性和作用的组合疗法,耗尽,持续性和机制的评估。他们有助于加快概念证明至临床汽车T细胞应用的批判性翻译。在本综述中,我们讨论了在人源化小鼠中受益的汽车T细胞治疗领域的创新发展,由多个例子说明。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号